CAJ | 학술논문

目的探讨乌司他丁联合抗真菌药物治疗侵袭性念珠菌感染的有效性和可能机制。方法雄性昆明小鼠60只，经CTX预处理后腹腔注射白念珠菌混悬液，制作侵袭性念珠菌感染小鼠模型，随机分成对照组（n=20）、低剂量组（n=20）和高剂量组（n=20）。对照组给予抗真菌药物治疗，低剂量组给予抗真菌药物联合乌司他丁（1×104 U/kg）治疗，高剂量组给予抗真菌药物联合乌司他丁（5×104 U/kg）治疗，观察3组7 d生存率、肝组织细胞因子和血淋巴细胞亚群水平。结果侵袭性念珠菌感染小鼠模型制作成功。高剂量组第7天生存率显著高于对照组（70%v s 30%，P=0.011）。低剂量组和高剂量组第7天肝组织IL-10均显著低于对照组（P<0.05）。低剂量组和高剂量组第7天小鼠CD4+/CD8+比例均显著高于对照组（P<0.05）。结论高剂量乌司他丁可以改善侵袭性念珠菌感染小鼠7d生存率，机制可能与提高细胞免疫功能和降低免疫抑制的发生有关。
목적탐토오사타정연합항진균약물치료침습성념주균감염적유효성화가능궤제。방법웅성곤명소서60지，경CTX예처리후복강주사백념주균혼현액，제작침습성념주균감염소서모형，수궤분성대조조（n=20）、저제량조（n=20）화고제량조（n=20）。대조조급여항진균약물치료，저제량조급여항진균약물연합오사타정（1×104 U/kg）치료，고제량조급여항진균약물연합오사타정（5×104 U/kg）치료，관찰3조7 d생존솔、간조직세포인자화혈림파세포아군수평。결과침습성념주균감염소서모형제작성공。고제량조제7천생존솔현저고우대조조（70%v s 30%，P=0.011）。저제량조화고제량조제7천간조직IL-10균현저저우대조조（P<0.05）。저제량조화고제량조제7천소서CD4+/CD8+비례균현저고우대조조（P<0.05）。결론고제량오사타정가이개선침습성념주균감염소서7d생존솔，궤제가능여제고세포면역공능화강저면역억제적발생유관。
Objective To investigate the effects and mechanism of Ulinastatin(UTI) combined with antifungal agents in treatment of invasive Candida infections (ICI). Methods Sixty Kunming mice were randomly assigned to control group, low-dose group and high-dose group (20 in each group). The model of ICI was reproduced by intraperitoneal injection of White monilial suspension after CTX pretreatment. Mice in control group were treated with antifungal agents. Mice in low-dose group and high-dose group were treated with UTI (1×104 U/kg or 5×104 U/kg) and antifungal agents. Survival rate, cytokine in liver tissue and blood lymphocyte subsets were compared among these groups. Results There was significant difference in survival rate between control group (30%) and high-dose group (70%), P=0.011. There was no significant difference in survival rate between other groups. There were significant differences in IL-10 among three groups, P<0.05. There were significant differences in CD3+rate, CD4+rate and CD8+rate between control group and high-dose group, P<0.05. There were significant differences in CD4+/CD8+rate among three groups, P< 0.05. Conclusion High-dose UTI can improve survival rate in mice with ICI through improving cellular immune and reducing immunosuppression.